Open AccessThe Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists
Author(s) -
Tjalling Bosse,
Sigurd Lax,
Nadeem R. AbuRustum,
Xavier MatíasGuiu
Publication year - 2021
Publication title -
international journal of gynecological pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.925
H-Index - 77
eISSN - 1538-7151
pISSN - 0277-1691
DOI - 10.1097/pgp.0000000000000755
Subject(s) - medicine , clinical trial , cervical cancer , oncology , predictive value , adenocarcinoma , human papillomavirus , biomarker , predictive marker , immunotherapy , pathology , cancer , biology , biochemistry
To review the scientific evidence related to predictive biomarkers in cervical adenocarcinoma (ADC). The authors reviewed the literature regarding predictive biomarkers in cervical ADC. There were several limitations: (1) there is an overlap between predictive and prognostic biomarkers, as the vast majority of patients are treated with anticancer strategies; (2) in many studies and clinical trials, cervical ADC patients are included in a large series of patients predominantly composed of cervical squamous cell carcinomas; and (3) in most of the studies, and clinical trials, there is no distinction between human papillomavirus (HPV)-associated and HPV-independent cervical ADCs, or between various histologic subtypes. Results obtained from a small group of studies confirm that cervical ADCs exhibit distinct molecular features as compared with squamous carcinomas, and that there are different molecular features between different types of cervical ADCs. Promising areas of interest include ERBB2 (HER2) mutations and PD-L1 expression as predictive biomarkers for anti-HER2 treatment and immunotherapy, respectively. To date, no definitive data can be obtained from the literature regarding predictive biomarkers for cervical ADC. Clinical trials specifically designed for endocervical ADC patients are required to elucidate the predictive value of HER2 mutations and PD-L1 expression. The distinction between HPV-associated and HPV-independent cervical ADCs as well as early involvement of pathologists in the design of future clinical trials are needed to identify new predictive biomarkers in cervical ADC.